High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis

Abozaid, Hanan S.; Imam, Hisham; Abdelaziz, Marwa; El-Hammady, Dina H.; Fathi, Nihal; Fürst, Daniel E.

doi:10.1016/j.semarthrit.2017.05.005

Cited by 20 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prospective study on 55 patients with SSc and clinically signi cant upper GI tract symptoms found a moderate correlation between the re ux scale of the UCLA GIT 2.0 with endoscopic oesophagitis; the re ux subscale was also discriminative between patients with and without pathologic ndings on oesophageal manometry (18). Another study on 40 patients with SSc, of whom 85% reported upper GI tract symptoms, found an association of higher re ux and total UCLA GIT 2.0 scores with decreased amplitude of distal oesophageal contractions (19). A very recent study on 31 patients with SSc, assessing esophageal motility dysfunction by scintigraphy, found a signi cant association of oesophageal emptying activity with the GIT 2.0 re ux score, but not with the other subscales and the total UCLA GIT 2.0 score (20).…”

Section: Discussionmentioning

confidence: 96%

“…Data on the associations of the UCLA GIT 2.0 with objective upper GI tract ndings are scarce. Previous studies analysed smaller groups of selected patients with SSc, in whom GI tract investigation and completion of the UCLA GIT 2.0 were performed systematically and within a narrow time interval (18,19,20). A prospective study on 55 patients with SSc and clinically signi cant upper GI tract symptoms found a moderate correlation between the re ux scale of the UCLA GIT 2.0 with endoscopic oesophagitis; the re ux subscale was also discriminative between patients with and without pathologic ndings on oesophageal manometry (18).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument as a Clinical Decision Aid in the Routine Clinical Care of Patients With Systemic Sclerosis

Zampatti

Garaiman

Jordan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background and objectivesThe University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture gastrointestinal (GI) tract morbidity in patients with systemic sclerosis (SSc). The aims of this study were to determine in a large SSc cohort if the UCLA GIT 2.0 is able to discriminate patients for whom a rheumatologist with experience in SSc would recommend an oesophago-gastro-duodenoscopy (EGD), and if it could identify patients with endoscopically proven oesophagitis or with any pathologic finding on EGD. Methods We selected patients fulfilling the ACR/EULAR 2013 criteria for SSc from our EUSTAR center having completed at least once the UCLA GIT 2.0 questionnaire, and we collected data on gastrointestinal symptoms and EGD from their medical charts. We analysed by general linear mixed effect models several parameters, including UCLA GIT 2.0, considered as potentially associated with the indication of EGD, as well as with endoscopic oesophagitis and any pathologic finding on EGD.Results We identified 346 patients (82.7% female, median age 63 years, median disease duration 10 years, 23% diffuse cutaneous SSc) satisfying the inclusion criteria, who completed UCLA GIT 2.0 questionnaires at 940 visits. EGD was recommended at 169 visits. In multivariable analysis, UCLA GIT 2.0 and some of its subscales (reflux, distention/bloating, social functioning) were associated with the indication of EGD. In 177 EGD performed in 145 patients, neither the total ULCA GIT 2.0 score nor any of its subscales were associated with endoscopic oesophagitis, nor with any pathologic EGD findings.ConclusionsIn a real-life setting, the UCLA GIT 2.0 was able to detect patients with SSc who had an indication for EGD. This supports the utilization of the UCLA GIT 2.0 as a decision aid in routine care for upper GI tract investigation of patients with SSc.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument as a Clinical Decision Aid in the Routine Clinical Care of Patients With Systemic Sclerosis

Zampatti

Garaiman

Jordan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The UCLA SCTC GIT 2.0 scale has been extensively validated in patients with SSc (38,39). Its usefulness is further substantiated in comparison with objective tests (40,41). The reflux and distention/bloating subscales correlated with upper GI tests such as the lactulose breath test, gastroesophageal endoscopy, and esophageal manometry (41).…”

Section: Gastrointestinal Measuresmentioning

confidence: 99%

“…The reflux and distention/bloating subscales correlated with upper GI tests such as the lactulose breath test, gastroesophageal endoscopy, and esophageal manometry (41). Both distal esophageal amplitude and lower esophageal sphincter resting pressure measured by high‐resolution manometry negatively correlated with the reflux subscale score and the total UCLA SCTC GIT score (40).…”

Section: Gastrointestinal Measuresmentioning

confidence: 99%

An Update of Outcome Measures in Systemic Sclerosis

Chang

Pope

2020

Arthritis Care & Research

View full text Add to dashboard Cite

“…Additionally, administering treatment protocols involving antacid and prokinetic agents and taking simple precautions such as bedhead elevation may prevent longterm complications including recurrent aspirations and lung injury, thereby improving patients' quality of life. [7] The aim of this study was to evaluate the demographic, endoscopic, manometric, and 24-hour esophageal pH test results in SS patients presenting with esophageal symptoms in our society. Twenty-six patients diagnosed with SS were included in the study.…”

Section: Introductionmentioning

confidence: 99%

Sistemik Skleroz’da Özofagus Tutulumu ve Gastroözofageal Reflü Hastalığı: Üçüncü Basamak Deneyimi

Bacaksız

Öztürk

Arı

et al. 2021

Journal of Contemporary Medicine

View full text Add to dashboard Cite

In this study, we investigated the demographic features, endoscopic, manometric, and 24-hour pH monitoring findings of patients with SS. Materials and Method:Twenty-six patients with SS who presented with dysphagia or heartburn complaints were identified. Patients' files, endoscopic, manometric, and 24-hour ph monitoring findings of the esophagus were examined.Results: All of the patients were symptomatic. The average age of 26 patients was 47.9 years and 96% were women. 46.1% of them applied with the complaint of heartburn and 53.9% with the complaint of dysphagia. The frequency of esophagitis in patients with SS was found to be significantly higher (p=0.005). Pathological reflux was detected in 90% of the patients with SS who underwent 24-hour pH monitoring and it was significantly higher (p=0.013). The mean esophageal body resting pressure in the patient with SS group was -0.73 mmHg and was significantly lower than that of control group (p<0.001). The mean resting LES pressure in the patient with SS group was 3.3 mmHg and was significantly lower than that of control group (p=0.028). Conclusion:Esophageal involvement is a hallmark manifestation of SS and typically occurs secondary to heartburn and dysphagia. In our society, the incidence of Gastroesophageal Reflux Disease (GERD) and GERD-related complications is high in SS patients with esophageal symptoms. It is important to refer these patients to experienced gastroenterology centers to be evaluated by endoscopic and then other diagnostic methods.

show abstract

High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis

Cited by 20 publications

References 26 publications

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument as a Clinical Decision Aid in the Routine Clinical Care of Patients With Systemic Sclerosis

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument as a Clinical Decision Aid in the Routine Clinical Care of Patients With Systemic Sclerosis

An Update of Outcome Measures in Systemic Sclerosis

Sistemik Skleroz’da Özofagus Tutulumu ve Gastroözofageal Reflü Hastalığı: Üçüncü Basamak Deneyimi

Contact Info

Product

Resources

About